Probiotics, prebiotics and postbiotics in community pharmacy practice: international regulatory challenges, product-specific evidence, and implications for pharmacist counseling in Türkiye

Probiotics, prebiotics, and postbiotics are increasingly incorporated into food supplements and other health-related products, yet their expanding commercial availability is accompanied by substantial heterogeneity in product characteristics, clinical evidence, and regulatory approaches. Prebiotics are substrates selectively utilized by host microorganisms that confer a health benefit, and their effects may depend on composition, dose, fermentability, and target population. This narrative review examines scientific, quality, regulatory, and practice-related considerations relevant to the evaluation of probiotics, prebiotics, and postbiotics, with particular emphasis on community pharmacy. Probiotic effects are generally preparation-specific and may depend on microorganism and strain identity, viable quantity, formulation, stability, indication, and target population. Prebiotic evaluation requires consideration of substrate identity, composition, purity, dose, stability, and evidence of selective utilization and health benefits. Postbiotics require a distinct evaluative approach emphasizing progenitor microorganisms, inactivation processes, composition, characterization, quantification, and demonstrated health benefits. Commercial-product studies indicate that labeling, microbial composition, viable counts, and declared prebiotic components do not invariably correspond to actual product characteristics, reinforcing the distinction between product information and product-specific clinical evidence. Regulatory approaches across selected jurisdictions, including the European Union, United States, Canada, Australia, Japan, and Türkiye, differ substantially in product classification, market-access pathways, permitted claims, and evidence requirements. These dimensions converge in community pharmacy, where pharmacists must relate specific product characteristics and evidence to individual patient needs. Accordingly, an evidence- informed framework encompassing product identity, regulatory status, quality, claim, product-specific evidence, and patient relevance may support transparent evaluation and evidence-informed counseling.